New scan agent shows promise for prostate cancer detection
NCT ID NCT06520449
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new imaging agent called 68Ga-NTA-476 for PET scans in 10 men with prostate cancer. The goal was to see how well it finds tumors compared to the standard scan, and to check for side effects. This was the first time this agent was used in humans, so safety and effectiveness were the main focus.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Melbourne Theranostic Innovation Centre
Melbourne, Victoria, 3051, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?